Acrivon Therapeutics News and Activities

Acrivon Therapeutics is a company listed under the stock ticker ACRV (US).

View the org chart displaying its 22 main executives

Most searched biographies at Acrivon Therapeutics

• Peter Blume-Jensen, Director, Chief Executive Officer and President
• Sharon Shacham, Director
• Santhosh Palani, Director

Popular executive movements at Acrivon Therapeutics

• Mansoor Mirza will join the company as Chief Medical Officer on Apr. 9, 2025  (posted on April 8 2025).
• Jean-Marie Cuillerot, Chief Medical Officer, will retire on Apr. 9, 2025  (posted on April 8 2025).
• Adam Levy who was Senior Vice President and Head, Investor Relations & Corporate Affairs, becomes Chief Financial Officer  (posted on March 17 2025).

Click here to view some more movements at Acrivon Therapeutics

Create your alert
to follow the executive moves at Acrivon Therapeutics.

Acrivon Therapeutics has 2,353 competitors including Incyte (United States (USA)), Anthos Therapeutics (United States (USA)) and Valneva (France).

Popular M&A news in Biotechnology

• Renasant Bio has just announced a $54 Million fundraising (posted on July 15 2025).
• Illimis Therapeutics has just announced a $42 Million fundraising (posted on July 14 2025).
• Nuclidium has just announced a $99 Million fundraising (posted on July 14 2025).

Popular contacts in Biotechnology

• Jasbir Seehra - Chief Executive Officer and Chairman of the Board at Keros Therapeutics
• Andrea Jackson - Director at Ultivue
• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group

Learn more about the Biotechnology industry

Press releases by Acrivon Therapeutics

• Events & Presentations | Acrivon Therapeutics, Inc.
• News Releases | Acrivon Therapeutics, Inc.
• Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic - Acrivon
• Eli Lilly Grants Acrivon Therapeutics Worldwide License to Develop DNA Damage Inhibitor Prexasertib
• Acrivon Therapeutics Raises $100M in Series B Funding
• Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368 - Acrivon
• Acrivon Therapeutics Announces the Appointments of Rasmus Holm-Jorgensen as Chief Financial Officer and Other Senior Executives - Acrivon
• Acrivon Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference - Acrivon
• View more press releases Close

Social media about Acrivon Therapeutics

• Acrivon Therapeutics on Wikipedia, Google News & Yahoo Finance
• Acrivon Therapeutics on LinkedIn, Twitter & YouTube